Plain-English translation of NCT06487377 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called IX001 TCR-T, which uses your own immune cells to fight pancreatic or colorectal cancer. The treatment targets cancers that have specific genetic mutations (KRAS mutations) and have stopped responding to standard chemotherapy. Researchers will collect your blood cells, grow specially trained immune cells in the lab, and then infuse them back into your body to attack your cancer.
Standard chemotherapy often stops working for advanced pancreatic and colorectal cancers, leaving patients with few treatment options. This medication is designed to work differently by training your own immune system to recognize and destroy cancer cells carrying specific genetic mutations, offering hope for patients who have run out of other options.
First, your blood will be collected and sent to a lab where your immune cells will be removed and specially trained to recognize your cancer. Once the cells are ready, you may receive medication to prepare your body, then the trained cells will be infused back into your body through an IV. You'll also receive additional medication (IL-2) to help the cells grow and work better. After that, you'll have regular follow-up visits for up to 96 weeks (nearly 2 years) to monitor your health, check how well the treatment is working, and watch for any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China